Artwork

Konten disediakan oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

1:28:38
 
Bagikan
 

Manage episode 334961100 series 1118501
Konten disediakan oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instruction on the use of next-generation triplets and quadruplets, maintenance strategies, and effective therapeutics in early relapse and treatment-refractory disease. Link cutting-edge evidence in MM to clinical decisions in your own practice—watch today! Upon completion of this activity, participants should be better able to: Cite current practice recommendations and clinical evidence surrounding the efficacy of novel proteasome inhibitor and IMiD options, novel antibody platforms, targeted agents, and cellular therapy across MM treatment settings; Select personalized, evidence-based regimens with novel components for the management of patients with newly diagnosed MM according to baseline comorbidities, functional status, and patient preferences, among other factors; Select evidence-based treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options into patient care; and Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome.
  continue reading

59 episode

Artwork
iconBagikan
 
Manage episode 334961100 series 1118501
Konten disediakan oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instruction on the use of next-generation triplets and quadruplets, maintenance strategies, and effective therapeutics in early relapse and treatment-refractory disease. Link cutting-edge evidence in MM to clinical decisions in your own practice—watch today! Upon completion of this activity, participants should be better able to: Cite current practice recommendations and clinical evidence surrounding the efficacy of novel proteasome inhibitor and IMiD options, novel antibody platforms, targeted agents, and cellular therapy across MM treatment settings; Select personalized, evidence-based regimens with novel components for the management of patients with newly diagnosed MM according to baseline comorbidities, functional status, and patient preferences, among other factors; Select evidence-based treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options into patient care; and Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome.
  continue reading

59 episode

Semua episode

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat